AC Immune SA (NASDAQ:ACIU) on Thursday released interim safety and efficacy results from the Phase 2 VacSYn trial of its anti-alpha-synuclein (a-syn) active immunotherapy ACI-7104.056 in early Parkinson’s disease.The results show, for the first time, that targeting a-syn pathology with an active immunotherapy could potentially slow the rate of progression of the disease. Disease-related biomarker results, including a-syn CSF levels and neurofilament light (NfL), suggest stabilization of its pathology.Elevat ...